Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: Henry Volquardsen who wrote (840)	1/15/1998 10:20:00 AM
From: MCorbley	Read Replies (1) \| Respond to of 1115

Henry, at least this must answer the concerns over the results of the clinical trials. I doubt that this whole deal was put together in the 2 weeks since the BMY announcement. And I am downright certain that nobody would offer to put up 100 million dollars at this stage to produce and market a drug if they weren't absolutely positive that the numbers are good enough to ensure approval by the FDA. I also find this sentence interesting: "The second stage of an additional $30 million dollars could be infused within 4 to 7 months upon receipt of an approvable letter from the FDA of topical LIDAKOL treatment of oral herpes." The "4 to 7 months" suggests a real optimism on their part that the FDA evaluation will proceed quickly. Michael